AVEO Oncology and Astellas Pharma, Inc. have terminated their worldwide collaboration and license agreement for the development and commercialization of investigational cancer agent tivozanib, effective August 2014, at which time rights will be returned to AVEO.   Astellas has exercised its right to terminate the agreement signed in 2011 for strategic reasons, based on the clinical status of the three indications studied. The companies have also agreed to discontinue the Phase II BATON study in ...